Ionis Pharmaceuticals IONS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's financing cash flow?
- Ionis Pharmaceuticals (IONS) reported financing cash flow of $57.26M in Q1 2026.
- How has Ionis Pharmaceuticals's financing cash flow changed year-over-year?
- Ionis Pharmaceuticals's financing cash flow increased by 2503.8% year-over-year, from $2.2M to $57.26M.
- What is the long-term trend for Ionis Pharmaceuticals's financing cash flow?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's financing cash flow has grown at a -0.0% compound annual growth rate (CAGR), from $676.35M to $675.84M.
- What does financing cash flow mean?
- The net cash flow resulting from borrowing, repaying debt, and issuing or repurchasing stock.
- How do you interpret financing cash flow?
- Positive values suggest net capital raising, while negative values indicate debt repayment or share buybacks.
- How does financing cash flow compare across companies?
- A standard cash flow statement component used to evaluate capital structure changes.